Cargando…

The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer

Triple negative breast cancer (TNBC) is an aggressive subtype that accounts for 15-20% of cases, with a higher incidence of relapse/death. Even with adjuvant chemotherapy, the 5 year distant metastasis-free survival rate remains low. A total of 452 tumor registry patients with TNBC and no evidence o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biswas, Tithi, Efird, Jimmy T., Prasad, Shreya, Jindal, Charulata, Walker, Paul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762543/ https://www.ncbi.nlm.nih.gov/pubmed/29348858 http://dx.doi.org/10.18632/oncotarget.22521

Ejemplares similares

Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics
por: Biswas, Tithi, et al.
Publicado: (2019)

On the Frontiers of Breast Cancer Diagnosis and Treatment: Current and Future Directions in a Rapidly Changing Field
por: Efird, Jimmy T., et al.
Publicado: (2022)

Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
por: Fane, Lauren S., et al.
Publicado: (2022)

Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women
por: Prasad, Shreya, et al.
Publicado: (2016)

Breast Cancer Disparities in Asian Women: The Need for Disaggregated Research
por: Fane, Lauren, et al.
Publicado: (2022)

Cone beam computed tomography—the need for future guidance
por: Efird, Jimmy T., et al.
Publicado: (2022)

A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation
por: Kang, Kylie H., et al.
Publicado: (2021)

The Association between Age, Comorbidities and Use of Radiotherapy in Women with Breast Cancer: Implications for Survival
por: Efird, Jimmy T., et al.
Publicado: (2018)

Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial
por: Biswas, Tithi, et al.
Publicado: (2021)

Using a Counting Process Method to Impute Censored Follow-Up Time Data
por: Efird, Jimmy T., et al.
Publicado: (2018)

Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Biswas, Tithi, et al.
Publicado: (2020)

Trauma Affecting Asian-Pacific Islanders in the San Francisco Bay Area
por: Bith-Melander, Pollie, et al.
Publicado: (2017)

The evidence for Mycobacterium avium subspecies paratuberculosis (MAP) as a cause of nonsolar uveal melanoma: a narrative review
por: Pierce, Ellen S., et al.
Publicado: (2022)

Refugee Policy Implications of U.S. Immigration Medical Screenings: A New Era of Inadmissibility on Health-Related Grounds
por: Hong, Mi-Kyung, et al.
Publicado: (2017)

The Prevention and Management of COVID-19: Seeking a Practical and Timely Solution
por: Jindal, Charulata, et al.
Publicado: (2020)

Race, insurance type, and stage of presentation among lung cancer patients
por: Efird, Jimmy T, et al.
Publicado: (2014)

Slow Burns: A Qualitative Study of Burn Pit and Toxic Exposures Among Military Veterans Serving in Afghanistan, Iraq and Throughout the Middle East
por: Bith-Melander, Pollie, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

A Pilot Study of Airborne Hazards and Other Toxic Exposures in Iraq War Veterans
por: Poisson, Chelsey, et al.
Publicado: (2020)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
por: Lehmann, Brian D., et al.
Publicado: (2016)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT)
por: Pu, Shengyu, et al.
Publicado: (2020)

Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer
por: Dou, He, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mqpi00pld5gquqtlvel53egork